20 July 2020
Delivered by MTPConnect, the Australian Government’s $45 million BioMedTech Horizons program is an initiative to support innovative collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key health challenges as well as maximise entrepreneurship and idea potential.
Round 3 of the program has selected 21 early-stage research projects to share in $18.8M – Congratulations to all recipients (listed below).
Anatomics Pty Ltd, Victoria, is developing digitally enabled skullcaps to monitor brain swelling in craniectomy patients to optimise timing of skull reconstruction surgery.
Anisop Holdings Pty Ltd, New South Wales, is developing a nano-optimised surface to prevent orthopaedic and dental implant infections.
Apollo Medical Imaging Technology Pty Ltd, Victoria, is developing an Artificial Intelligence-based clinical decision support software for guided acute stroke therapy.
Artrya Pty Ltd, Western Australia, is developing Artificial Intelligence methods for evaluating cardiac CT angiography and high-risk imaging biomarkers.
Atmo Biosciences Pty Ltd, Victoria, is developing an application of Atmo ingestible gas sensing capsule to diagnose Irritable Bowel Syndrome (IBS) and Small Intestinal Bacterial Overgrowth (SIBO).
Bionic Vision Technologies Pty Ltd, Victoria, is developing an implantable vision system and algorithm in their Bionic Eye Generation 3 device to restore functional vision for blind patients.
Carbon Cybernetics, Victoria, is developing a high-resolution cortical recording of the brain for the prediction and prevention of epileptic seizures.
Ear Science Institute Australia, Western Australia, is advancing the commercialisation of its ClearDrum® device, which is an acoustically-optimised silk fibroin implant for the treatment of chronic middle ear disease.
Ferronova Pty Ltd, South Australia, is working to improve colorectal cancer outcomes with hybrid cancer tracers.
Hemideina, Victoria, is developing a miniature, low-energy wireless power and data transmission system for implantable medical devices.
Inventia Life Science Pty Ltd, New South Wales, is developing a 3D bioprinting system for intraoperative skin regeneration.
Merunova Pty Ltd, New South Wales, is developing an augmented digital re-construction and re-visualisation of spine MRI for the personalised diagnosis of back pain.
Miniprobes Pty Ltd, South Australia, is developing a smart brain biopsy needle for faster, safer neurosurgery.
Neuromersiv Pty Ltd, New South Wales, is advancing the commercialisation of its hand and arm wearable device for use with the Neuromersiv virtual reality rehabilitation system.
Northern Research Pty Ltd, New South Wales, is advancing the commercialisation of its PulseVAD pulsatile rotary blood pump that is designed to treat patients suffering from a form of Congestive Heart Failure (CHF) for which, at present, there is no effective treatment.
OncoRes Medical Pty Ltd, Western Australia, is developing compact wireless technology for improvement in the accuracy during breast conserving surgery.
Optiscan Pty Ltd, Victoria, is developing its non-invasive confocal endomicroscopy system to enhance oral cancer screening and surgical margin assessment.
Seer, Victoria, is developing personalised epilepsy treatment via mobile and wearable monitoring.
Synchron Australia Pty Ltd, Victoria, is advancing the commercialisation of its Stentrode; a minimally-invasive brain-computer interface being designed to enable people with paralysis to restore functional independence by engaging in activities of daily living such as email communication, text messaging and online shopping, by controlling apps and external devices through thought alone, and without requiring open brain surgery.
VenstraMedical Pty Ltd, New South Wales, is enhancing the development of a transcatheter blood pump system for Cardiogenic Shock and Hemodynamically Compromised patients.
Zip Diagnostics, Victoria, is establishing domestic capabilities for combined R&D and manufacture of point-of-care diagnostics.
This funding, BMTH3.0, is delivered via the Medical Research Future Fund (MRFF), and administered by MTPConnect. Read the original announcement here.